Market Overview

HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies

Share:
HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
Related GNCA
The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
Related
The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo's Positive Trial Results, Insys Earnings
Benzinga's Top Upgrades, Downgrades For June 22, 2018
Interpace Diagnostics to Present at the –…th Annual Next Generation Dx Summit —…–8 (GuruFocus)

Analysts at H.C. Wainwright initiated coverage Thursday on two pharmaceutical companies developing cancer-related vaccines and treatments.

Interpace: Efficient Diagnosis, Expanding Reimbursement Coverage

Analyst Raghuram Selvaraju initiated coverage on Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) with a Buy rating and a 12-month price target of $3. 

Interpace — a molecular diagnostics company with a focus on gastrointestinal, endocrine and respiratory cancers — offers assays that can accurately distinguish between patients at low and high risks of developing cancer, reducing the need for surgery and lowering overall health care costs, Selvaraju said.

The company’s primary revenue drivers are PancraGEN, for pancreatic cysts and solid lesions, and ThyGenX and ThyraMIR for thyroid nodules, according to H.C. Wainwright. Both tests offer positive predictive value  well above industry standards, yielding higher diagnosis accuracy, the analyst said. 

Reimbursement coverage of Intercept’s cancer diagnostics assays has increased over the past two years, Selvaraju said. PancraGEN, ThyGenX and ThyraMIR are covered by Aetna, Cigna, UnitedHealthcare, Oxford and Blue Cross Blue Shield, the analyst said. 

At the time of publication, shares of Interpace were trading up nearly 3 percent at $1.04.

Genocea: Personalized Vaccines Could Become Industry Standard

Analyst Joseph Pantginis initiated coverage on Genocea Biosciences Inc (NASDAQ: GNCA) with a Buy rating and a 12-month price target of $5. 

Genocea’s focus on personalized neo-antigen cancer vaccines could “add to the standard of care for leading tumor indications," Pantginis said in a Thursday note. 

The analyst’s bullish outlook is primarily driven by GEN-009, a personalized neo-antigen anti-cancer vaccine guided by the T-cell antigen discovery platform ATLAS, which gives it a “distinct advantage in vaccine development," the analyst said. 

Genocea is planning to file an investigative new drug application followed by a trial in mid-2018, according to H.C. Wainwright.

“The clinical study is expected to include a variety of tumor types including melanoma, non-small cell lung cancer, head and neck cancer and urothelial cancer.”

At the time of publication Thursday, Genocea shares were up 6.31 percent to $1.18. 

Related Links:

Street Abandons Genocea On Strategic Shift, CEO Says Oncology Focus Wasn't 'Sudden'

The Current State Of The Breast Cancer Treatment Space

Latest Ratings for GNCA

DateFirmActionFromTo
Mar 2018H.C. WainwrightInitiates Coverage OnBuy
Mar 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Feb 2018BairdInitiates Coverage OnOutperform

View More Analyst Ratings for GNCA
View the Latest Analyst Ratings

Posted-In: H.C. Wainwright Joseph PantginisBiotech Price Target Initiation Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (GNCA + IDXG)

View Comments and Join the Discussion!

Zosano Pharma Is The Latest Low Float Stock To Make A Huge Move

Elon Musk's Thoughts About China, Tariffs And Import Duties: 'Like Competing In Olympic Race Wearing Lead Shoes'